Capital Securities released a research report on April 24 stating that it gave Rongtai Health (603579.SH) a purchase rating. The main reasons for the rating include: 1) annual revenue declined under pressure, and the revenue growth rate rose at an inflection point in Q4; 2) falling raw material prices & optimization of product and customer structures, and improvement in profit levels. (Mainichi Keizai Shimbun)
首创证券4月24日发布研报称，给予荣泰健康（603579.SH）买入评级。评级理由主要包括：1）全年收入承压下滑，Q4单季度营收增速拐点向上；2）原料价格回落&产品及客户结构优化，盈利水平改善。（每日经济新闻）
Capital Securities released a research report on April 24 stating that it gave Rongtai Health (603579.SH) a purchase rating. The main reasons for the rating include: 1) annual revenue declined under pressure, and the revenue growth rate rose at an inflect
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated